Profile data is unavailable for this security.
About the company
Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.
- Revenue in GBP (TTM)47.20k
- Net income in GBP-926.91k
- Incorporated2004
- Employees6.00
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 122 349 7700
- Fax+44 122 349 7701
- Websitehttp://www.sareum.co.uk/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4d Pharma PLC | 490.00k | -67.69m | 122.60m | 115.00 | -- | 3.09 | -- | 250.21 | -0.4438 | -0.4438 | 0.0034 | 0.22 | 0.0112 | -- | 0.195 | 4,260.87 | -154.55 | -32.46 | -182.79 | -35.41 | -- | -- | -13,813.67 | -13,963.36 | 4.18 | -54.63 | 0.0248 | -- | 153.08 | -- | -7.88 | -- | -27.01 | -- |
| Scancell Holdings Plc | 0.00 | -6.85m | 175.27m | 22.00 | -- | 6.42 | -- | -- | -0.0134 | -0.0134 | 0.00 | 0.0335 | 0.00 | -- | -- | 0.00 | -31.68 | -42.18 | -38.68 | -45.64 | -- | -- | -- | -- | -- | -4.33 | 0.1248 | -- | -- | -- | 2.16 | -- | -- | -- |
| Arix Bioscience PLC | 468.00k | 38.88m | 179.56m | 330.00 | 5.61 | 0.649 | -- | 383.68 | 0.2476 | 0.2476 | 0.0035 | 2.14 | 0.0018 | -- | 0.2998 | 1,418.18 | 14.50 | -- | 14.61 | -- | -- | -- | 8,307.05 | -- | -- | -- | 0.0005 | -- | -5.73 | -- | 281.25 | -- | -- | -- |
| e-Therapeutics plc | 317.00k | -3.68m | 180.61m | 18.00 | -- | 10.64 | -- | 569.74 | -0.0097 | -0.0097 | 0.0009 | 0.033 | 0.0332 | -- | 6.82 | 17,611.11 | -38.58 | -44.60 | -40.02 | -48.16 | 100.00 | 100.00 | -1,162.15 | -3,490.09 | -- | -- | 0.0017 | -- | -30.48 | -- | -56.97 | -- | -13.19 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -16.99m | 180.87m | 30.00 | -- | 72.33 | -- | -- | -0.3521 | -0.3521 | 0.00 | 0.047 | 0.00 | -- | -- | 0.00 | -153.87 | -134.84 | -248.86 | -258.18 | -- | -- | -- | -8,392.69 | -- | -93.58 | 0.5557 | -- | -- | -- | -27.78 | -- | 5.82 | -- |
| Circassia Group PLC | 27.10m | -19.40m | 188.82m | 247.00 | -- | 2.90 | -- | 6.97 | -0.0468 | -0.0396 | 0.0658 | 0.1559 | 0.256 | 1.87 | 1.74 | 109,716.60 | -18.33 | -11.82 | -24.20 | -13.79 | 67.90 | 76.33 | -71.59 | -106.47 | 1.40 | -- | 0.0254 | -- | -30.92 | 17.22 | -59.52 | -- | 10.76 | -- |
| Bioventix PLC | 10.93m | 6.73m | 190.14m | 16.00 | 28.53 | 16.09 | 27.69 | 17.40 | 1.28 | 1.28 | 2.08 | 2.27 | 0.8342 | 2.83 | 2.64 | -- | 51.37 | 52.37 | 55.02 | 55.55 | 92.52 | 92.30 | 61.58 | 65.29 | 11.02 | 31.82 | -- | 70.90 | 5.98 | 14.65 | -6.54 | 14.01 | 65.43 | 27.46 |
| Eco Animal Health Group Plc | 105.61m | 8.16m | 193.01m | 207.00 | 23.85 | 2.31 | 10.50 | 1.83 | 0.1195 | 0.1195 | 1.53 | 1.23 | 0.9751 | 2.75 | 3.41 | 510,178.80 | 15.37 | 10.55 | 20.66 | 13.14 | 50.77 | 48.53 | 15.77 | 14.62 | 3.04 | 24.16 | 0.0155 | 47.19 | 46.46 | 17.51 | 109.45 | 6.21 | -30.72 | -29.40 |
| Animalcare Group Plc | 75.10m | 96.00k | 223.54m | 211.00 | 2,384.62 | 2.74 | 24.36 | 2.98 | 0.0016 | 0.0016 | 1.25 | 1.36 | 0.6114 | 2.72 | 6.80 | 355,900.50 | 0.0782 | -- | 0.0909 | -- | 53.23 | -- | 0.1278 | -- | 1.02 | 6.91 | 0.159 | -- | -0.8858 | -- | 117.49 | -- | -- | -- |
| Sareum Holdings Plc | 47.20k | -926.91k | 227.18m | 6.00 | -- | 162.18 | -- | 4,813.24 | -0.0003 | -0.0003 | 0.00001 | 0.0004 | 0.0316 | -- | 0.7098 | 7,866.67 | -62.02 | -48.02 | -71.74 | -51.95 | -- | -- | -1,963.79 | -9,651.86 | -- | -24.86 | 0.00 | -- | -- | -- | 32.12 | -- | -- | -- |
| Allergy Therapeutics plc | 84.33m | 2.89m | 227.84m | 601.00 | 113.42 | 4.77 | 32.46 | 2.70 | 0.0031 | 0.0031 | 0.1275 | 0.0745 | 0.9676 | 2.11 | 11.80 | 140,317.80 | 3.31 | 1.01 | 4.19 | 1.33 | 73.79 | 74.38 | 3.42 | 0.9213 | 2.58 | 10.78 | 0.1871 | 0.00 | 7.83 | 11.69 | -59.11 | -- | 15.77 | -- |
| Redx Pharma PLC | 6.61m | -17.95m | 236.74m | 52.00 | -- | 11.05 | -- | 35.79 | -0.0802 | -0.0802 | 0.0306 | 0.0778 | 0.2407 | -- | 3.63 | -- | -65.30 | -46.97 | -84.52 | -90.73 | 68.23 | -- | -271.33 | -92.26 | -- | -10.18 | 0.4286 | -- | 81.57 | -- | -113.36 | -- | -30.43 | -- |
| Creo Medical Group PLC | 22.33m | -21.16m | 298.49m | 245.00 | -- | 5.09 | -- | 13.37 | -0.1346 | -0.1346 | 0.1419 | 0.3244 | 0.2782 | 3.12 | 5.08 | 102,891.70 | -26.37 | -- | -31.21 | -- | 45.54 | -- | -94.79 | -- | 2.17 | -53.68 | 0.1703 | -- | 69,899.11 | -- | -27.68 | -- | -- | -- |
| Avacta Group Plc | 4.15m | -22.09m | 319.68m | 123.00 | -- | 5.98 | -- | 77.09 | -0.0937 | -0.0937 | 0.0175 | 0.2106 | 0.0612 | 8.77 | 1.04 | 33,715.45 | -32.63 | -- | -34.79 | -- | 59.49 | -- | -532.77 | -- | 8.74 | -72.10 | 0.0343 | -- | -- | -- | -- | -- | -- | -- |
| Synairgen plc | 0.00 | -13.92m | 336.24m | 18.00 | -- | 3.92 | -- | -- | -0.0986 | -0.0986 | 0.00 | 0.4259 | 0.00 | -- | -- | 0.00 | -30.05 | -30.56 | -31.80 | -33.63 | -- | -- | -- | -431.93 | 25.86 | -- | 0.0015 | -- | -- | -- | -258.20 | -- | 50.02 | -- |
Data as of Oct 21 2021. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX
24.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hargreaves Lansdown Stockbrokers Ltd.as of 02 Jul 2021 | 363.00m | 10.79% |
| Hargreaves Lansdown Asset Management Ltd.as of 02 Jul 2021 | 196.66m | 5.84% |
| HSBC Global Asset Management (UK) Ltd.as of 02 Jul 2021 | 138.17m | 4.11% |
| Jarvis Investment Management Ltd.as of 02 Jul 2021 | 37.93m | 1.13% |
| HSBC Bank Plc (Market-Maker)as of 02 Jul 2021 | 25.39m | 0.75% |
| IG Markets Ltd.as of 02 Jul 2021 | 22.61m | 0.67% |
| The Share Centre Ltd.as of 02 Jul 2021 | 12.86m | 0.38% |
| KW Investment Management Ltd.as of 02 Jul 2021 | 9.87m | 0.29% |
| Tilney Investment Management Services Ltd.as of 02 Jul 2021 | 6.57m | 0.20% |
| Walker Crips Investment Management Ltd.as of 02 Jul 2021 | 6.26m | 0.19% |
More ▼
Data from 30 Sep 2020 - 01 Oct 2021Source: FactSet Research Systems Inc.
